Neurochemical evidence based suggested therapy for safe management of epileptogenesis

Navjot Kaur1, Tanveer Singh1, Sandeep Kumar1

  • 1Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.

Insights

This study reveals that resistant animals exhibit natural neurochemical defenses against epileptogenesis, offering potential targets for new treatments. These findings highlight endogenous mechanisms for managing epilepsy development.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Existing antiepileptic drugs primarily offer antiseizure effects, failing to prevent epileptogenesis.
  • Previous clinical trials for epileptogenesis management have been unsuccessful, highlighting a need for better preclinical models.
  • Understanding the neurochemical underpinnings of epileptogenesis is crucial for developing effective interventions.

Purpose of the Study:

  • To investigate a neurochemistry-based approach for managing epileptogenesis.
  • To delineate the neurochemical alterations in the amygdala, cortex, and hippocampus during kindling.
  • To identify endogenous neurochemical defense mechanisms in kindling-resistant animals.

Main Methods:

  • Kindling epileptogenesis induced in male Swiss albino mice using subconvulsive pentylenetetrazole (PTZ) over 42 days.
  • Behavioral evaluations conducted post-PTZ administration.
  • Neurochemical analysis of brain regions (amygdala, cortex, hippocampus) in naive, kindled, and kindling-resistant animals.

Main Results:

  • 60% of animals developed kindling, characterized by a decreased seizure threshold and associated behavioral deficits (anxiety, depression, cognitive impairment).
  • Kindling-resistant animals showed no such deficits and exhibited distinct neurochemical profiles.
  • Kindled animals displayed altered glutamate-GABA neurotransmission, decreased taurine, glycine, d-serine, and monoamine levels, with elevated indoleamine 2,3-dioxygenase (IDO) activity.
  • Kindling-resistant animals showed elevated GABA, taurine, tryptophan, serotonin, glycine, and d-serine levels, with decreased IDO activity.

Conclusions:

  • Kindled animals exhibit neurochemical changes that promote epileptogenesis.
  • Kindling-resistant animals possess endogenous antiepileptogenic mechanisms involving specific neurochemicals and reduced IDO activity.
  • These endogenous mechanisms represent potential safe pharmacological targets for managing epileptogenesis.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.6K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
867